Cardero Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Los Altos Hills CA United States (2008)
Status: Defunct (2009)

Organization Overview

First Clinical Trial
2013
NCT01856868
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Cardero Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

epicatechin (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 2)

Cerebellar Ataxia (Phase 2)

Friedreich Ataxia (Phase 2)

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1